Biocon Says New Biosimilars To Drive Growth For Next 5 Years

Biocon Plays The Biosimilars Card

Talking Point: e-Learning To Drive Next Leg Of Growth For Aptech?

Why earnings growth could see a drastic change over next two years

Expect Cumulative Earnings Growth Can Be 50% Over Next 3 Years, Says Manish Gunwani

DTI projects double-digit growth for PH creative industries in the next 3 years

Granules Confident Of 25% Earnings Growth Over Next 3 Years: MD Chigurupati

Mindtree Confident Of Double-Digit Growth For Next Few Years

Gov't unveils plans to support innovative growth over next five years

Nation View: United Nation report suggest good GDP growth in next two years

Korea's potential growth rate expected to fall to 2.5% for next 4 years

Birla OPUS' Growth Projection in Next 2-3 Years | NDTV Profit

Look to achieve double-digit growth in next 5 years, says Ashish Vohra of Reliance Nippon Life

What is medical interchangeability and how does it apply to Biosimilars?

EU will den Zugang zu Biosimilars für Patienten fördern

Biosimilars: a cheaper yet equally efficient alternative to name-brand medications

Biocon Rallies On FDA's Letter On Mylan's Biosimilar

Biocon Outlook On The Biosimilar Sales | NDTV Profit

Kiran Mazumdar Shaw of Biocon on biosimilar & business outlook

Biocon Jumps On FDA's Letter On Mylan's Biosimilar

Biocon Eyes First Mover Advantage With Launch Of Neulasta Biosimilar

Growth momentum to continue in Q2, H2 due to trastuzumab launch, says Biocon

Biocon sees FY20 as a strong year in terms of generics biz growth in US

Biocon Management On Q1 Result And Growth Strategy For FY22

Keywords for President Park's 3 years in office

Keywords for President Park's 3 years in office